Schizophrenia and Schizoaffective Disorders

Schizophrenia and schizoaffective disorders are severe mental conditions characterized by hallucinations, delusions, and mood disturbances. The Journal of Clinical Psychiatry offers a deep dive into these disorders, emphasizing their diagnosis, management, and underlying causes. Our expert editors ensure content is both clinically relevant and actionable, aiding psychiatrists in offering effective and compassionate care.

Page 24

Recently published articles about Schizophrenia/Schizoaffective Disorders

JCP
Economic Impact of Cognitive Impairment and Negative Symptoms in Schizophrenia
Review Article

August 21, 2024

Patients with schizophrenia and cognitive impairment had a 100% increase in relapse-related hospitalizations and ER visits versus patients with no (or only mild) cognitive impairment.
Christoph U. Correll, Pin Xiang, Kaushik Sarikonda, et al
JCP
Adjunctive Treatment Targeting Multiple Mechanisms in Schizophrenia
Narrative Review

August 19, 2024

While the pathophysiology of schizophrenia is complex, treatments with novel pharmacological actions that target these systems are of interest as adjunctive treatment for schizophrenia.
Bruce J. Kinon, Stefan Leucht, Carol Tamminga, et al
JCP
Aripiprazole Lauroxil Initiation Regimens
Original Research

August 12, 2024

In separate studies of the two initiation methods, the numbers of people who had side effects were similar, and most side effects were mild.
Roger W. Sommi, Stephen R. Saklad, Peter J. Weiden, et al
PCC
Clozapine: Its Use and Monitoring
Rounds in the General Hospital

July 30, 2024

The authors provide the latest information on clozapine use, including when your patients should receive or avoid taking it, what laboratory tests are required before and during administration, and...
Desta S. Lissanu, Chirag M. Vyas, Carol S. Lim, et al
Research Helps Clear Up Confusion About Cognition
news

July 22, 2024

New research provides insights into cognitive challenges, including age-related decline and the effects of psychiatric medications.
Weekly Mind Reader: Emotion Deficits Link Borderline Personality and Eating Disorders?
news

July 5, 2024

This week explores the link between BP and EDs, managing treatment-resistant schizophrenia, and a new FDA-approved Alzheimer's drug.
PCC
Evaluation and Management of Treatment-Resistant Schizophrenia
Rounds in the General Hospital

July 2, 2024

If you have ever been uncertain about how to evaluate patients with a chronic psychotic illness or struggled over how best to manage treatment-resistant schizophrenia, then this case vignette...
Carol S. Lim, Abigail L. Donovan, Chirag M. Vyas, et al
Breaking Down Emerging Research on Catatonia in Schizophrenia
news

June 26, 2024

Emerging research has convinced modern psychiatry to reconsider catatonia as a symptom of schizophrenia rather than a standalone condition.
Studies Clear Up Confusion Surrounding Clozapine
news

June 17, 2024

A growing contingent has called for fewer clozapine restrictions, while concerns about side effects and treatment disparities persist.
Weekly Mind Reader: Clozapine Research, Esmethadone Efficacy, and Our First Reader Mailbag
news

May 16, 2024

This week we report on a bevy of clozapine research, a promising Esmethadone case study, and let our readers take it from there.
JCP
Antipsychotic Medication Continuation vs Taper and Discontinuation
Clinical and Practical Psychopharmacology

May 15, 2024

Dr Andrade discusses two studies that examined the outcomes of gradual, individualized antipsychotic dose reduction and discontinuation in patients with psychosis.
Chittaranjan Andrade
JCP
Clozapine Exposure and Risk of Hematologic Malignancies in Veterans with Schizophrenia
Original Research

May 15, 2024

Clozapine exposure of at least 5 years was associated with hematologic malignancy, and the increased risk was dose-dependent.
Delaney R. Brainerd, Bruce Alexander, Marshall J. Tague, et al

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe